Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 13 years, Shin Nippon Biomedical Laboratories's highest 3-Year average EPS without NRI Growth Rate was 63.30% per year. The lowest was -41.00% per year. And the median was 12.50% per year.
Shin Nippon Biomedical Laboratories (OTCPK:SBLOF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Shin Nippon Biomedical Laboratories Earnings per Share (Diluted) Related Terms
Shin Nippon Biomedical Laboratories Earnings per Share (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Earnings per Share (Diluted) Chart
SBLOF vs TMO, DHR, IDXX: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's PE Ratio distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's PE Ratio falls into.
Shin Nippon Biomedical Laboratories Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.71 mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a Earnings per Share (Diluted) of $0.71 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Shin Nippon Biomedical Laboratories and its competitors. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #126 out of 158 companies in the Medical Diagnostics & Research industry, placing it in the top 79.7%.
Is Shin Nippon Biomedical Laboratories' Earnings per Share (Diluted) too high?
Shin Nippon Biomedical Laboratories' current Earnings per Share (Diluted) is $0.71. The Medical Diagnostics & Research industry median Earnings per Share (Diluted) is 10.75. Shin Nippon Biomedical Laboratories' value of $0.71 is 93.4% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #126 out of 158 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Earnings per Share (Diluted) compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #126 out of 158 companies for Earnings per Share (Diluted). This places Shin Nippon Biomedical Laboratories in the lower half of its industry. The industry median Earnings per Share (Diluted) is 10.75. Shin Nippon Biomedical Laboratories' value of $0.71 is 93.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.75, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Earnings per Share (Diluted) of $0.71 is 93.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Earnings per Share (Diluted) is $0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Earnings per Share (Diluted) of $0.71. The stock's GF Value™ is $12.83, compared to a current price of $9.16 — trading 28.6% below its estimated fair value. The current Earnings per Share (Diluted) is $0.71 and 93.4% below the Medical Diagnostics & Research industry median of 10.75. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Earnings per Share (Diluted) is $0.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 28.6% below its estimated GF Value™ of $12.83.
Key valuation signals for SBLOF:
Earnings per Share (Diluted): $0.71
GF Value™: $12.83 vs. price of $9.16 (28.6% below fair value)
Industry Position: 93.4% below the Medical Diagnostics & Research median (#126 of 158)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for SBLOF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
